Choline transporter gene variation is associated with attention-deficit hyperactivity disorder

Journal of Neurodevelopmental Disorders

Volumn 1, Issue 4, 2009, Pages 252-263

  English, Brett A ^a   Hahn, Maureen K ^a   Gizer, Ian R ^b,d   Mazei Robison, Michelle ^a   Steele, Angela ^a   Kurnik, Daniel M ^a   Stein, Mark A ^c   Waldman, Irwin D ^b   Blakely, Randy D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Choline; Polymorphism; SLC5A7; Transporter

Indexed keywords

EID: 80052969033     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1007/s11689-009-9033-8     Document Type: Article

References (87)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Assocation; 2004. [test revision[. 2004.
2. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther. 2003;25:3065-83.
3. Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:373-83.
4. Faraone SV, Doyle AE. The nature and heritability of attentiondeficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2001;10:299-316. viii-ix.
5. Mick E. Genetics of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2008;17:261-84.
6. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2005;57:1313-23.
7. Faraone SV, Khan SA. Candidate gene studies of attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):13-20.
8. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol. 2008;28:S39-45.
9. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology. 2005;49:724-36.
10. Kim JJ, Shih JC, Chen K, Chen L, Bao S, Maren S, et al. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc Natl Acad Sci U S A. 1997;94:5929-33.
11. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2006;103:19164-9.
12. Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry. 2006;11:187-95.
13. Rowe DL, Hermens DF. Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development. Expert Rev Neurother. 2006;6:1721-34.
14. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003;64(Suppl 9):11-7.
15. Kent L, Green E, Holmes J, Thapar A, Gill M, Hawi Z, et al. No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder. Am J Med Genet. 2001; 105:686-9.
16. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000;23:120-6.
17. Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, et al. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science. 2000;289:633-7.
18. Sarter MF, Bruno JP. Cognitive functions of cortical ACh: lessons from studies on trans-synaptic modulation of activated efflux. Trends Neurosci. 1994;17:217-21.
19. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273-80.
20. Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Brain Res Rev. 2005;48:98-111.
21. Hasselmo ME, McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res. 2004;145:207-31.
22. Todd RD, Lobos EA, Sun LW, Neuman RJ. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry. 2003;8:103-8.
23. Kent L, Middle F, Hawi Z, Fitzgerald M, Gill M, Feehan C, et al. Nicotinic acetylcholine receptor alpha4 subunit gene polymorphism and attention deficit hyperactivity disorder. Psychiatr Genet. 2001;11:37-40.
24. Okuda T, Haga T. Functional characterization of the human highaffinity choline transporter. FEBS Lett. 2000;484:92-7.
25. Ferguson SM, Savchenko V, Apparsundaram S, Zwick M, Wright J, Heilman CJ, et al. Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J Neurosci. 2003;23:9697-709.
26. Ferguson SM, Blakely RD. The choline transporter resurfaces: New roles for synaptic fesicles? Mol Interv. 2004;4:22-37.
27. Atweh S, Simon JR, Kuhar MJ. Utilization of sodium-dependent high affinity choline uptake in vitro as a measure of the activity of chloinergic neurons in vivo. Life Sci. 1975;17:1535-44.
28. MV AS, Parikh V, Kozar R, Sarter M. Increased capacity and density of choline transportes situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. J Neurosci. 2005;25:3851-6.
29. Okuda T, Okamura M, Kaitsuka C, Haga T, Gurwitz D. Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate. J Biol Chem. 2002;277:45315-22.
30. Apparsundaram S, Ferguson SM, George AL Jr, Blakely RD. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Biochem Biophys Res Commun. 2000;276:862-7.
31. Bazalakova MH, Wright J, Schneble EJ, McDonald MP, Heilman CJ, Levey AI, et al. Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice. Genes Brain Behav. 2007;6:411-24.
32. Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, et al. Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Genes Brain Behav. 2008;7:487-95.
33. Neumann SA, Lawrence EC, Jennings JR, Ferrell RE, Manuck SB. Heart rate variability is associated with polymorphic variation in the choline transporter gene. Psychosom Med. 2005;67:168-71.
34. Neumann SA, Brown SM, Ferrell RE, Flory JD, Manuck SB, Hariri AR. Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function. Biol Psychiatry. 2006;60:1155-62.
35. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-8.
36. Ambrosini PJ. Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS). J Am Acad Child Adolesc Psychiatry. 2000;39:49-58.
37. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374-82.
38. Waldman I, Rowe D, Abramowitz A, Kozel S, Mohr J, Sherman S, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet. 1998;63:1767-76.
39. Achenbach TM, McConaughy SH, Howell CT. Child/adolescent behavioral and emotional problems: implications of crossinformant correlations for situational specificity. Psychol Bull. 1987;101:213-32.
40. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet. 1998;63:1767-76.
41. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD. Sequence variation in the human dopae transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology. 2005.
42. Wigginton JE, Abecasis GR. PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics. 2005;21:3445-7.
43. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet. 1993;52:506-16.
44. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol. 2003;25:115-21.
45. Lange C, Laird NM. On a general class of conditional tests for family-based association studies in genetics: the asymptotic distribution, the conditional power, and optimality considerations. Genet Epidemiol. 2002;23:165-80.
46. Waldman ID, Robinson BF, Feigon SA. Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity. Genet Epidemiol. 1997;14:699-704.
47. Waldman ID, Robinson BF, Rowe DC. A logistic regression based extension of the TDT for continuous and categorical traits. Ann Hum Genet. 1999;63:329-40.
48. Lange C, Blacker D, Laird NM. Family-based association tests for survival and times-to-onset analysis. Stat Med. 2004;23:179-89.
49. Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM. Using the noninformative families in family-based association tests: a powerful new testing strategy. Am J Hum Genet. 2003;73:801-11.
50. Rabinowitz D, Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum Hered. 2000;50:211-23.
51. Laird NM, Cuenco KT. Regression methods for assessing familial aggregation of disease. Stat Med. 2003;22:1447-55.
52. Epstein MP, Waldman ID, Satten GA. Improved association analyses of disease subtypes in case-parent triads. Genet Epidemiol. 2006;30:209-19.
53. Rosenthal R. Meta-analytic procedures for social research. 2nd ed. Thousand Oaks: Sage; 1991.
54. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19:3127-31.
55. Rowe D, Stever C, Giedinghagen L, Gard J, Cleveland H, Terris S, et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry. 1998;3:419-26.
56. Faraone SV, Biederman J, Weber W, Russell RL. Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: Results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry. 1998;37:185-93.
57. Lahey BB, Applegate B, McBurnett K, Biederman J, et al. DMSIV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry. 1994;151:1673-85.
58. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry. 1995;34:629-38.
59. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-24.
60. Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience. 2000;95:933-52.
61. Kobayashi Y, Isa T. Sensory-motor gating and cognitive control by the brainstem cholinergic system. Neural Netw. 2002;15:731-41.
62. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry. 1999;40:57-87.
63. Daviss WB. A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. J Child Adolesc Psychopharmacol. 2008;18:565-71.
64. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand. 2004;110:408-15.
65. Galera C, Bouvard MP, Encrenaz G, Messiah A, Fombonne E. Hyperactivity-inattention symptoms in childhood and suicidal behaviors in adolescence: the Youth Gazel Cohort. Acta Psychiatr Scand. 2008;118:480-9.
66. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigidcompulsive behaviors. Am J Hum Genet. 2005;77:265-79.
67. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wildtype transporters. J Neurosci. 2003;23:4470-8.
68. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al. Orthostatic intolerance and tachycardia associated with norepinephrine- transporter deficiency. N Engl J Med. 2000;342: 541-9.
69. Sitte HH, Farhan H, Javitch JA. Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol Interv. 2004;4:38-47.
70. Schmid JA, Just H, Sitte HH. Impact of oligomerization on the function of the human serotonin transporter. Biochem Soc Trans. 2001;29:732-6.
71. Kocabas AM, Rudnick G, Kilic F. Functional consequences of homo-but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters. J Neurochem. 2003;85:1513-20.
72. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: A role in the cognitive dysfunction in Attention-Deficit/ Hyperactivity Disorder? Behavioural Brain Research. 2006;175: 201-11.
73. Vakalopoulos C. Neurocognitive deficits in major depression and a new theory of ADHD: a model of impaired antagonism of cholinergic-mediated prepotent behaviours in monoamine depleted individuals. Med Hypotheses. 2007;68:210-21.
74. Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545-53.
75. Miller AD, Blaha CD. Nigrostriatal dopamine release modulated by mesopontine muscarinic receptors. Neuroreport. 2004;15: 1805-8.
76. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci. 2005;6:48-56.
77. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A. 2001;98: 15312-7.
78. Carta M, Stancampiano R, Tronci E, Collu M, Usiello A, Morelli M, et al. Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats. Neuroscience. 2006;139: 1163-72.
79. Mattsson A, Pernold K, Ogren SO, Olson L. Loss of cortical acetylcholine enhances amphetamine-induced locomotor activity. Neuroscience. 2004;127:579-91.
80. Lee J, Laurin N, Crosbie J, Ickowicz A, Pathare T, Malone M, et al. Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes Brain Behav. 2008;7:53-60.
81. Chen JM, Ferec C, Cooper DN. A systematic analysis of diseaseassociated variants in the 3' regulatory regions of human proteincoding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants. Hum Genet. 2006;120:301-33.
82. Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB, et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1345-54.
83. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009.
84. Neale BM, Lasky-Su J, Anney R, Franke B, Zhou K, Maller JB, et al. Genome-wide association scan of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1337-44.
85. Rommelse NN, Arias-Vasquez A, Altink ME, Buschgens CJ, Fliers E, Asherson P, et al. Neuropsychological endophenotype approach to genome-wide linkage analysis identifies susceptibility loci for ADHD on 2q21.1 and 13q12.11.AmJ HumGenet. 2008;83:99-105.
86. Zhou K, Dempfle A, Arcos-Burgos M, Bakker SC, Banaschewski T, Biederman J, et al. Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1392-8.
87. Arcos-Burgos M, Castellanos FX, Pineda D, Lopera F, Palacio JD, Palacio LG, et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet. 2004;75:998-1014.